Medicamentos genéricos, ¿equivalentes a los de referencia? ¿qué está sucediendo?

Fernández Martínez, M. Nélida; Diez Láiz, Raquel; Rodríguez Lago, José Manuel; Sánchez Valdeón, Leticia; Casado Verdejo, Inés; Sahagún Prieto, Ana M.
Rev. Rol enferm ; 42(6): 424-429, jun. 2019. ilus
Artículo en Español | IBECS (España) | ID: ibc-186984

Documentos relacionados

  1. Harmonization of summaries of product characteristics (SmPCs) of drugs with the same active ingredients: an evaluation of SmPCs of the most frequently prescribed active substances.
  2. Why sedative hypnotics often fail in development.
  3. Diving into Batch-to-Batch Variability of Topical Products-a Regulatory Bottleneck.
  4. Approximate confidence limit for the reference scaled bioequivalence with a parallel design.
  5. Comparative evaluation of dissolution profiles of the generic drug lamivudine 150 mg tablet marketed in Peru vs. the innovative Epivir.
  6. Willingness to pay brand premiums for generic medicines in Kenya: A bidding game experiment.
  7. [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
  8. Analysis of Medicine Prices in New Zealand and 16 European Countries.
  9. Generic Drugs Not as Safe as FDA Wants You to Believe.
  10. How the FDA Ensures High-Quality Generic Drugs.